Saturday 17 October 2026
Export CDT’s income statement to Excel — free account
CDT Equity Inc.
In the quarter to June 2026, EPS grew 98.0% and free cash flow grew 78.9%, each against the same quarter a year earlier.
0.24
0.03
+14.29%
Follow CDT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 744,750,016.00 | 71,250,000.00 | 3,825,000.00 | 7,875.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 791,249,984.00 | 1,875,000,064.00 | 396,750,016.00 | 13,725,000.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | 7 | 6 | 4 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | 0 | (5) | (1) | (18) | (39) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | — | 0 | (5) | (1) | (18) | (39) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 3 | 4 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | 0.00 | (0.13) | (0.80) | (615,592.30) | (294,474.40) | |||||
| Cash flow | — | — | — | — | — | 0.00 | (0.06) | (11.53) | 0.00 | (155,550.00) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (8,080.00) | |||||
| Free cash flow | — | — | — | — | — | 0.00 | (0.06) | (11.53) | 0.00 | (163,630.00) | |||||
| Book value | — | — | — | — | — | 0.01 | (0.27) | (0.68) | 0.00 | (71,700.00) | |||||
| Shares, m | — | — | — | — | — | 3 | 37 | 1 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (2) | (8) | (10) | (16) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | |||||
| Free cash flow | — | — | — | — | — | 0 | (2) | (8) | (10) | (16) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | (4) | 4 | (8) | (8) | ||||
| Total debt | — | — | — | — | — | 0 | 2 | — | — | — | |||||
| Net debt | — | — | — | — | — | 0 | 1 | (4) | (1) | (2) | |||||
| Shareholders’ equity | — | — | — | — | — | 0 | (10) | 0 | (7) | (7) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (4.13) | (4,481.43) | (14.80) | (311.85) | (796.99) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 97.08 | 10.15 | 491.09 | 561.83 | |||||
Negative figures in brackets.
Fundamentals updated 2 Oct 2026
Charts ten years each
CDT Equity Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SEELQ Seelos Therapeutics, Inc. | $700.0K | — (loss-making) | — (loss-making) | +11.90% (above 0%: growing) | n/m | +83.54% (above 0%: growing) | 100.00% | (834.84%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $640.0K | 0.0× | — (loss-making) | — | n/m | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $440.0K | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VINC Vincerx Pharma, Inc. | $250.0K | — (loss-making) | — | — | n/m | +42.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CDT CDT Equity Inc. | $240.0K | — (loss-making) | — | — | n/m | +78.92% (above 0%: growing) | — | 0.00% | |
| EFTR eFFECTOR Therapeutics, Inc. | $200.0K | — (loss-making) | — | +58.08% (above 0%: growing) | n/m | +4.86% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VRPX Virpax Pharmaceuticals, Inc. | $160.0K | — (loss-making) | — | — | n/m | +4.68% (above 0%: growing) | — | 0.00% | Compare |
| CERO CERo Therapeutics Holdings, Inc. | $140.0K | 0.0× | — | — | n/m | +49.65% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $345.0K | — | — | +11.90% | — | +23.65% | 0.00% | 0.00% |
CDT Equity Inc. (CDT) key facts
- CDT Equity Inc. (CDT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CDT traded at $0.24, a market capitalization of $240,000.00.
- Return on equity was 561.8% and debt-to-equity 0.00.